Dr. Zhang’s research aims on innovation of drug development, especially protein kinase inhibitors. He applies small molecules as chemical probes to decipher cell signaling networks and understand the mechanism of drug resistance in cancer. He has published more than 70 research articles in Nature, Cancer Research and other journals. The total number of citations of his research was more than 10,500, the first author or corresponding author was more than 3,500, h-index = 35. He obtained four international patents and several invented compounds are widely used for academic research. His reach led to a phase III clinical trial of BCR-ABL allosteric inhibitor Asciminib.